We believe that the identification of ALCAM/CD166 and β1 integrins as adhesion molecules that mediate the docking and uptake of CRC and OvC-derived EVs may contribute to the development of new therapeutic approaches aimed at blocking the peritoneal metastasis cascade promoted by EVs in CRC and OvC patients. Here, ALCAM is linked to colorectal carcinoma.